BioSpace News Archive

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its third quarter 2023 financial results and provide an operational update for the Company on Tuesday, November 7, 2023, before the market opens.

YS Biopharma Co., Ltd. announced that it has received written notification from the staff of the Listing Qualifications Department of the Nasdaq Stock Market LLC dated October 24, 2023, indicating that because the closing bid price of the Company’s ordinary shares for the last 31 consecutive business days was below US$1.00 per share, the Company no longer meets the Nasdaq minimum bid price requirement set forth in Nasdaq Listing Rule 5550.

RLS Radiopharmacies, the only Joint Commission-accredited radiopharmacy network in the U.S., announced it is expanding its business operations with the addition of radiopharmaceutical contract development

A large international study led by deCODE Genetics on the genetics of migraine provides novel insights into the biology of migraine enabling detection of rare variants protecting against migraine, opening an avenue for potential development of novel drug targets.

Epic Bio is presenting new data reflecting advances in its Gene Expression Modulation System (GEMS) platform, alongside additional preclinical data supporting the company’s lead program, EPI-321, in development for the treatment of facioscapulohumeral muscular dystrophy (FSHD).

Zenith Epigenetics Ltd. (“Zenith” or the “Company”), a global leader in epigenetics, announced today it has entered into an agreement with Cencora (formerly AmerisourceBergen) aimed at accelerating the commercialization of Zenith Epigenetics’ ZEN-3694 program.

Magritek has made benchtop NMR suitable for the rapid identification and quantitation of analytes during chemical reactions, in batch and continuous flow processes.